Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Name: Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
Published: 2020
License: Public Domain

Merck Sharp & Dohme LLC · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

papillomavirus infections, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Related documents